Investor Relations.
All material information for prospective and current investors of Quessentials Limited — financials, disclosures, governance documents, and the IPO calendar.
Issue structure & key terms.
A fresh issue combined with an offer for sale by existing shareholders. Final size and price band to be determined post-SEBI clearance and roadshow feedback.
Book-built IPO
Fresh issue + Offer for Sale (OFS) by existing shareholders, listing on NSE and BSE.
Capacity + Working Capital
Phase II Malur expansion, new processing site in Andhra Pradesh, working capital, and general corporate purposes.
₹10 per equity share
Price band, lot size and issue size to be intimated via the RHP at the time of issue opening.
ICICI · Axis Capital
Book-Running Lead Managers to the issue. Registrar to the issue: KFin Technologies.
IPO Calendar (indicative)
| Milestone | Status | Expected Date |
|---|---|---|
| DRHP filing with SEBI | Completed | Q4 FY25 |
| SEBI observations | In Progress | Q1 FY26 |
| Roadshows (domestic & international) | Upcoming | Q2 FY26 |
| RHP filing & price band announcement | Upcoming | Q2 FY26 |
| Issue open · close | Upcoming | Q3 FY26 |
| Listing on NSE & BSE | Upcoming | Q3 FY26 |
Dates are subject to SEBI clearance, market conditions and other regulatory considerations.
Why Quessentials,
why now.
Six structural drivers that, in our view, support the medium-term equity story. Full discussion in the DRHP, Section 4.
Category Leadership
Largest South-India processor of chia, sesame and panicum — a moat built on nine years of certifications, customer integration, and farmer networks.
Tailwinds in Superfoods
Global chia and quinoa demand expanding at ~9% CAGR. India is the world's #1 chia producer; we are positioned at the export node of that value chain.
Sticky Customer Base
1,000+ active customers, 87% revenue from exports, 12 of the top 20 global health-food brands on the active customer roster.
Operating Leverage
Phase II capacity expansion doubles output at marginal SG&A. EBITDA margin expansion of 250 bps modelled over FY26–FY28.
Natural FX Hedge
87% export revenue creates a structural USD/EUR receivable book — natural hedge against rupee weakness.
Governance Posture
Independent-majority board, Big-Four audit, quarterly disclosures, and SEBI-grade compliance from day one of listing.
Five years of disciplined growth.
Audited under Ind AS by a Big-Four firm. Detailed restated financial statements available in the DRHP, Section 5.
▲ 28% CAGR (FY20–FY24)
▲ 180 bps vs FY23
▲ Top quartile peer-set
▼ De-leveraged through FY24
Summary P&L (₹ Crore)
| Metric | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue from Operations | 55.2 | 71.6 | 94.8 | 118.4 | 148.2 |
| EBITDA | 5.8 | 8.2 | 11.7 | 15.2 | 21.6 |
| EBITDA Margin (%) | 10.5% | 11.5% | 12.3% | 12.8% | 14.6% |
| Profit After Tax | 2.4 | 3.7 | 5.9 | 8.1 | 12.4 |
| RoCE (%) | 11.2% | 14.8% | 17.4% | 20.1% | 22.4% |
| Net Debt / EBITDA (x) | 1.8x | 1.4x | 1.1x | 0.7x | 0.4x |
Restated audited financials per Ind AS. Refer to DRHP Section 5 for full statements, segmental disclosures, and accounting policies.
The full investor pack.
Statutory filings, annual reports, governance documents, and policy disclosures.
Committee composition.
All committees are constituted with independent-director majority where required by SEBI LODR and Companies Act 2013.
| Committee | Chair | Composition | Charter |
|---|---|---|---|
| Audit Committee | Independent Director · TBA | 3 members · 3 ID | View → |
| Nomination & Remuneration | Independent Director · TBA | 3 members · 2 ID, 1 NED | View → |
| Stakeholder Relationship | Independent Director · TBA | 3 members · 2 ID, 1 ED | View → |
| Risk Management | Independent Director · TBA | 4 members · 3 ID, 1 ED | View → |
| Corporate Social Responsibility | Independent Director · TBA | 3 members · 2 ID, 1 ED | View → |
| IPO Committee | Krishna Kanth (MD) | 5 members · 3 ID, 2 ED | View → |
ID: Independent Director · NED: Non-Executive Director · ED: Executive Director · MD: Managing Director
Speak directly
to the IR team.
For analyst meetings, institutional roadshow requests, or queries regarding the proposed IPO, please contact the Investor Relations office. We acknowledge all queries within one business day.
Investor Relations Office
Dedicated CFO and Company Secretary appointments to be intimated prior to RHP filing.
Important Disclaimer
Quessentials Limited has filed a Draft Red Herring Prospectus dated 15 March 2026 with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the website of SEBI at www.sebi.gov.in, BSE at www.bseindia.com, NSE at www.nseindia.com, and on the websites of the Book Running Lead Managers. Investors are advised to refer to the DRHP and the Red Herring Prospectus, when filed, for full details. Investment in equity shares involves a high degree of risk; investors should not invest any funds in this issue unless they can afford to take the risk of losing their investment. Investors are advised to refer to the section titled "Risk Factors" in the DRHP. The contents of this website are for general information only and do not constitute an offer, invitation, or solicitation in any jurisdiction.